Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 6/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | ADK | P55263 | 1/20 | 0.45 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | RNMT | O43148 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27428044 | 0.92 | ADORA3 (0.47) | SLC29A1ADORA3ADKDNPH1ADORA1 | |
| SCHEMBL27426411 | 0.90 | SLC29A1 (0.56) | SLC29A1ADORA3ADORA1 | |
| SCHEMBL27426410 | 0.86 | SLC29A1 (0.56) | SLC29A1ADORA3ADORA1 | |
| SCHEMBL27426560 | 0.85 | SLC29A1 (0.62) | SLC29A1ADORA3ADKADORA1 | |
| SCHEMBL27427484 | 0.85 | ADORA3 (0.48) | SLC29A1ADORA3ADKDNPH1ADORA1 | |
| SCHEMBL27427402 | 0.85 | SLC29A1 (0.58) | SLC29A1ADORA3DNPH1 | |
| SCHEMBL27427694 | 0.83 | SLC29A1 (0.56) | SLC29A1ADORA3 | |
| SCHEMBL27429696 | 0.82 | ADORA3 (0.48) | SLC29A1ADORA3ADKADORA1RNMT | |
| SCHEMBL27425390 | 0.81 | SLC29A1 (0.62) | SLC29A1ADORA3ADKADORA1 | |
| SCHEMBL27426665 | 0.81 | SLC29A1 (0.59) | SLC29A1ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024134541-A1 | HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2024-06-27 | — | — | WO | disclosed |